FDA approves TraceLink DSCSA pilot submission for network solutions
Delivering 2023 traceability by leveraging blockchain and digital recalls across a supply network.
TraceLink has announced the acceptance of its participation in the FDA Pilot Project Program under the Drug Supply Chain Security Act (DSCSA). TraceLink’s pilot project focuses on two workstreams: an interoperable blockchain network solution and digital recalls across a supply network, both intended to bring together participants of all sizes from across the pharmaceutical supply chain to enhance patient safety and address challenging business processes through network connectivity and innovative software solutions.
“We are excited to move forward on the FDA pilot project with our customers, representing companies of different sizes, complexities, and operational use cases from all segments of the supply chain. Combining insights from these leading companies with TraceLink’s digital supply network will garner compelling information that will contribute to the innovation, security, and interoperability of the U.S. supply chain,” said Shabbir Dahod, President and CEO, TraceLink. “The objectives of the FDA pilot program align closely with TraceLink’s mission of developing new solutions that will drive visibility and collaboration, resulting in not only increased security and safety, but ultimately, the improvement of human life.”
Unique to TraceLink’s pilot project is the inclusion of a very diverse set of industry stakeholders including large pharmaceutical manufacturers, biopharmaceutical companies, contract manufacturers, repackagers, wholesale distributors, major retail pharmacy chains, diversified healthcare systems, third-party logistics providers and returns processors. The two workstreams will explore new approaches for interoperable information sharing and the use of verification and notification for enhancing patient safety, while maintaining data privacy and ownership.
2023 Traceability Workstream: TraceLink’s Interoperable Blockchain Network Solution with Trace Histories
The blockchain workstream will bring together end to end stakeholders from the supply chain to evaluate how blockchain can be used to help companies meet 2023 DSCSA transaction information gathering requirements.
This workstream will leverage TraceLink’s blockchain solution, Trace Histories as one of the tools to develop a blueprint for the industry for an open, interoperable network to fulfill the requirements for full unit level traceability across the supply chain. Trace Histories is a distributed ledger network that enables safe and secure information exchange between authorized partners with a unique “gather upon request” model. Unlike other industry initiatives that require use of a single blockchain system throughout the industry, Trace Histories was purpose-built for standardization to support interoperability across blockchain and non-blockchain networks.
The objective of this workstream is to provide key learnings for each stakeholder to prepare for and meet the 2023 deadline as an industry.
Product Recalls Workstream: Digital Recalls Across the Supply Network
TraceLink’s digital recalls worksteam is intended to evaluate and enhance current recall verification and notification processes within the pharmaceutical supply chain by leveraging both lot level and serialization data on a digital supply chain network. Current recall processes within the industry are largely manual and time-consuming, creating inefficiencies and putting patient safety at risk. While individual companies have standing recalls processes in place, the existing recalls process is costly and ineffective when viewed across the supply network. In working toward the objectives of this workstream, pilot participants will evaluate different methods of effectively exchanging information on a network and coordinating with supply chain partners to prevent recalled product from reaching patients.
Both workstreams will gather ongoing participant feedback and are expected to be complete in the fall of 2019.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance